Outlook Therapeutics director buys 400K shares

Outlook Therapeutics director Kurt J. Hilzinger increased his personal stake by buying 400,000 shares of Common Stock in an open-market purchase.

Rhea-AI Filing Summary

Outlook Therapeutics director Kurt J. Hilzinger increased his personal stake by buying 400,000 shares of Common Stock in an open-market purchase. The shares were acquired at an average price of $0.4413 per share. Following this transaction, he directly owns 423,655 shares of Outlook Therapeutics common stock.

Insider Trade Summary

Net Buyer: 400,000 shares

Net Buy 1 txn

Insider HILZINGER KURT J

Role Director

Bought 400,000 shs ($177K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	400,000	$0.4413	$177K

Holdings After Transaction: Common Stock — 423,655 shares (Direct)

Key Figures

Shares purchased: 400,000 shares Purchase price: $0.4413 per share Shares owned after transaction: 423,655 shares +2 more

5 metrics

Shares purchased 400,000 shares Open-market purchase of Common Stock

Purchase price $0.4413 per share Average transaction price on purchase date

Shares owned after transaction 423,655 shares Direct holdings following the reported trade

Net buy shares 400,000 shares Net buy direction in transaction summary

Buy transactions count 1 transaction Number of buy entries in this Form 4

Key Terms

open-market purchase, Common Stock, non-derivative, net-buy

4 terms

open-market purchase financial

"transaction_action: open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

non-derivative financial

"transaction_type: non-derivative"

net-buy financial

"netBuySellDirection: net-buy"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Outlook Therapeutics (OTLK) disclose?

Outlook Therapeutics disclosed that director Kurt J. Hilzinger completed an open-market purchase of 400,000 shares of Common Stock. The transaction reflects a direct acquisition of shares rather than an option exercise or derivative conversion, indicating an increase in his equity position.

How many Outlook Therapeutics shares did Kurt J. Hilzinger buy and at what price?

Kurt J. Hilzinger bought 400,000 Outlook Therapeutics Common Stock shares at an average price of $0.4413 per share. This open-market purchase represents his direct acquisition of additional shares based on prevailing market prices on the transaction date.

What are Kurt J. Hilzinger’s Outlook Therapeutics holdings after this Form 4 trade?

After the reported purchase, Kurt J. Hilzinger directly holds 423,655 shares of Outlook Therapeutics Common Stock. The Form 4 indicates these shares are held with direct ownership, meaning they are attributed personally rather than through an intermediary entity or trust.

Was the Outlook Therapeutics Form 4 transaction a buy or a sell?

The Form 4 transaction was a buy. It is coded as an open-market purchase, with 400,000 Common Stock shares acquired. The transaction direction is explicitly classified as a net buy, with no reported sales or derivative exercises in this filing.

Does this Outlook Therapeutics Form 4 involve derivatives or options?

No, this Form 4 reports only a non-derivative transaction in Common Stock. The derivativeSummary is empty, and the filing shows no option exercises, conversions, or other derivative-related trades, focusing solely on the open-market share purchase by the director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/27/2026 - 03:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HILZINGER KURT J

(Last) (First) (Middle)

C/O OUTLOOK THERAPEUTICS, INC.

111 S. WOOD AVE, UNIT #100

(Street)

ISELIN NEW JERSEY 08830

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Outlook Therapeutics, Inc. [ OTLK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/26/2026		P		400,000	A	$0.4413	423,655	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Lawrence Kenyon, Attorney-in-Fact	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)